EGFR and non-small cell lung carcinoma: She presented a significant clinical and morphological response under sequential TKIs treatment (afatinib, osimertinib, and then neratinib).<h4>Conclusion</h4>A non-small cell lung cancer (NSCLC) with rare compound mutation exon 18-exon 18 (G719A and E709A) and EGFR amplification can be overcome with adapted sequential second- and third-generation TKIs.